Search Header Logo
It's in the Genes: Health Care ETF Outperforms the S&P 500

It's in the Genes: Health Care ETF Outperforms the S&P 500

Assessment

Interactive Video

Business, Engineering

University

Practice Problem

Hard

Created by

Wayground Content

FREE Resource

The Ark Genomic Revolution ETF (ARC G) focuses on companies in the genomics industry, bridging healthcare and technology. It primarily includes biotech, healthcare services, and pharmaceuticals. The fund holds around 40 companies, such as Illumina and Bristol Myers Squibb, involved in advancements like targeted therapeutics and CRISPR. The genomics industry is valued over $15 billion, with an annual growth forecast of 8.5% until 2025. ARC G has outperformed the S&P 500 since its launch, managing $430 million in assets with a 0.75% expense ratio. It is actively managed and rated positively by Bloomberg Intelligence.

Read more

5 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What industries does the Ark Genomic Revolution ETF primarily target?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

What types of advancements do the companies held by the Ark Genomic Revolution ETF focus on?

Evaluate responses using AI:

OFF

3.

OPEN ENDED QUESTION

3 mins • 1 pt

What is the estimated worth of the global genomics industry?

Evaluate responses using AI:

OFF

4.

OPEN ENDED QUESTION

3 mins • 1 pt

How has the performance of the Ark Genomic Revolution ETF compared to the S&P 500?

Evaluate responses using AI:

OFF

5.

OPEN ENDED QUESTION

3 mins • 1 pt

What is the expense ratio of the Ark Genomic Revolution ETF?

Evaluate responses using AI:

OFF

Access all questions and much more by creating a free account

Create resources

Host any resource

Get auto-graded reports

Google

Continue with Google

Email

Continue with Email

Classlink

Continue with Classlink

Clever

Continue with Clever

or continue with

Microsoft

Microsoft

Apple

Apple

Others

Others

Already have an account?